Client Story
Presentation
Biopsy revealed metastatic poorly differentiated carcinoma but could not determine primary site of cancer.
Additional molecular profiling ordered by provider on the biopsy tissue did not reveal primary cancer site.
Disease quickly progressed on 1st line treatment (carboplatin/paclitaxel); pivoted to pembrolizumab monotherapy.
PHM Actions
PHM Care team determined results could be suggestive of kidney cancer.
Coordinated tumor tissue of origin testing (CancerTypeID) which quickly confirmed kidney cancer (96% probability).
Optimized local care by shifting from previous local provider to leading expert provider at UCSF.
Arranged second opinion consult with international kidney cancer KOL; confirmed cancer primary site and appropriate treatment plan for kidney cancer 1st line standard of care.
Outcome
Further characterized tumor and identified additional treatment options as well as plans for next line of therapy should 1st line treatment be unsuccessful.
The PHM Difference
“We are in a much better place than we were a month ago, thanks to you. You’ve put us on a good path, we feel really good here.”
Discover our Why Wall